Literature DB >> 12500206

Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.

Agustín Albillos1, Antonio de la Hera, Mónica González, Jose-Luis Moya, Jose-Luis Calleja, Jorge Monserrat, Luis Ruiz-del-Arbol, Melchor Alvarez-Mon.   

Abstract

Intestinal bacterial overgrowth and translocation, both common in cirrhosis with ascites, may lead to the activation of monocytes and lymphocytes, increased levels of proinflammatory cytokines, and enhanced synthesis of nitric oxide present in cirrhosis. Bacterial endotoxin promotes the synthesis of lipopolysaccharide (LPS)-binding protein (LBP), and forms a LPS-LBP complex that binds to CD14. This study was designed to evaluate LBP levels and their correlation to the immune response and the hemodynamic status in cirrhotic patients. Plasma LBP, endotoxin, soluble CD14 (sCD14), cytokines, renin, nitrites, and systemic vascular resistance were determined before and 4 weeks after norfloxacin or placebo in 102 cirrhotic patients and 30 controls. LBP was elevated in 42% of ascitic cirrhotic patients (15.7 +/- 0.7 versus 6.06 +/- 0.5 microg/mL, P <.01). In 60% of high LBP patients, endotoxin was within normal range. Among ascitic patients, those with high LBP showed greater (P <.05) levels of sCD14, tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), nitrites + nitrates (NOx)/creatinine, and renin, and lower vascular resistance. In the cirrhotic patients with high LBP, norfloxacin normalized (P <.01) LBP (from 16.6 +/- 0.5 to 5.82 +/- 0.8 microg/mL) and sCD14; reduced the level of cytokines, NOx/creatinine, and renin; and increased vascular resistance; but lacked effect in patients with normal LBP. Portal pressure was unchanged after norfloxacin in another group of 18 cirrhotic patients with high and 19 with normal LBP. In conclusion, the subset of ascitic cirrhotic patients with marked immune and hemodynamic derangement is identified by increased LBP levels. Amelioration of these abnormalities by norfloxacin suggests the involvement of enteric bacteria or their products in the triggering of the process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12500206     DOI: 10.1053/jhep.2003.50038

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  107 in total

1.  Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis.

Authors:  Gabriel L Reep; Roger D Soloway
Journal:  World J Hepatol       Date:  2011-08-27

Review 2.  Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.

Authors:  Brian Erly; William D Carey; Baljendra Kapoor; J Mark McKinney; Mathew Tam; Weiping Wang
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

3.  Lipopolysaccharide binding protein is down-regulated during acute liver failure.

Authors:  Grace L Su; Robert J Fontana; Kartik Jinjuvadia; Jill Bayliss; Stewart C Wang
Journal:  Dig Dis Sci       Date:  2012-01-26       Impact factor: 3.199

Review 4.  Infection, coagulation, and variceal bleeding in cirrhosis.

Authors:  U Thalheimer; C K Triantos; D N Samonakis; D Patch; A K Burroughs
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 5.  Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Authors:  Andrew H Talal; Charles S Venuto; Islam Younis
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

Review 6.  Markers of bacterial translocation in end-stage liver disease.

Authors:  Ioannis Koutsounas; Garyfallia Kaltsa; Spyros I Siakavellas; Giorgos Bamias
Journal:  World J Hepatol       Date:  2015-09-18

Review 7.  Update on adrenal insufficiency in patients with liver cirrhosis.

Authors:  Anca Trifan; Stefan Chiriac; Carol Stanciu
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 8.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Proteomic evidence of bacterial peptide translocation in afebrile patients with cirrhosis and ascites.

Authors:  Rocío Caño; Lucía Llanos; Pedro Zapater; Sonia Pascual; Pablo Bellot; Claudia Barquero; Miguel Pérez-Mateo; José Such; Rubén Francés
Journal:  J Mol Med (Berl)       Date:  2010-01-20       Impact factor: 4.599

Review 10.  Kidney-liver pathophysiological crosstalk: its characteristics and importance.

Authors:  Olivia Capalbo; Sofía Giuliani; Alberta Ferrero-Fernández; Paola Casciato; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2019-09-23       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.